Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

574 ARTÍCULOS , VIENDO DEL 526 AL 540

Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review

Blackman J, Swirski M, Clynes J, Harding S, Leng Y, Coulthard E.

J Sleep Res. 2021 Aug;30(4):e13229. doi: 10.1111/jsr.13229. Epub 2020 Dec 2.

Zingiber officinale ameliorates Alzheimer's disease and Cognitive Impairments: Lessons from preclinical studies

Talebi M, İlgün S, Ebrahimi V, Talebi M, Farkhondeh T, Ebrahimi H, Samarghandian S.

Biomed Pharmacother. 2021 Jan;133:111088. doi: 10.1016/j.biopha.2020.111088. Epub 2020 Dec 15.

Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies

Zetterberg H, Bendlin BB.

Mol Psychiatry. 2021 Jan;26(1):296-308. doi: 10.1038/s41380-020-0721-9. Epub 2020 Apr 6.

Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use

Gavrilova SI, Alvarez A.

Med Res Rev. 2021 Sep;41(5):2775-2803. doi: 10.1002/med.21722. Epub 2020 Aug 17.

European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment

Frederiksen KS, Nielsen TR, Winblad B, Schmidt R, Kramberger MG, Jones RW, Hort J, Grimmer T, Georges J, Frölich L, Engelborghs S, Dubois B, Waldemar G.

Eur J Neurol. 2021 Jul;28(7):2147-2155. doi: 10.1111/ene.14668. Epub 2020 Dec 23.

Effects of vitamin E supplementation on the risk and progression of AD: a systematic review and meta-analysis

Wang W, Li J, Zhang H, Wang X, Zhang X.

Nutr Neurosci. 2021 Jan;24(1):13-22. doi: 10.1080/1028415X.2019.1585506. Epub 2019 Mar 22.

Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders

Benfante R, Di Lascio S, Cardani S, Fornasari D.

Aging Clin Exp Res. 2021 Apr;33(4):823-834. doi: 10.1007/s40520-019-01359-4. Epub 2019 Oct 3.

A meta-analysis of peripheral tocopherol levels in age-related cognitive decline and Alzheimer's disease

Ashley S, Bradburn S, Murgatroyd C.

Nutr Neurosci. 2021 Oct;24(10):795-809. doi: 10.1080/1028415X.2019.1681066. Epub 2019 Oct 29.

Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease

Shimura H, Saiko A, Hayashi A, Hattori N, Urabe T.

BMC Neurol. 2021 Feb 10;21(1):61. doi: 10.1186/s12883-021-02098-8.

Melatonin Receptor as a Drug Target for Neuroprotection

Wongprayoon P, Govitrapong P.

Curr Mol Pharmacol. 2021;14(2):150-164. doi: 10.2174/1874467213666200421160835.

Current Updates in Transdermal Therapeutic Systems and Their Role in Neurological Disorders

Yadav N, Mittal A, Ali J, Sahoo J.

Curr Protein Pept Sci. 2021;22(6):458-469. doi: 10.2174/1389203721999201111195512.

Advances in Stem Cell Therapy for Brain Diseases via the Intranasal Route

Dali P, Shende P.

Curr Pharm Biotechnol. 2021;22(11):1466-1481. doi: 10.2174/1389201021666201218130947.

Parkinson´s and Alzheimer´s Diseases and Natural Products: Pathologies and Medication of the New Times

Nabavi SM, Sobarzo-Sánchez E.

Curr Neuropharmacol. 2021;19(2):112-113. doi: 10.2174/1570159X1902201231153120.

The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models

MacDougall G, Brown LY, Kantor B, Chiba-Falek O.

Mol Ther. 2021 Mar 3;29(3):949-972. doi: 10.1016/j.ymthe.2021.01.001. Epub 2021 Jan 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias